COVID19: Oxford Study of Predictors of Infectivity (OSPREY) [COVID-19]

  • Research type

    Research Study

  • Full title

    COVID19: Oxford Study of Predictors of Infectivity (OSPREY)

  • IRAS ID

    289529

  • Contact name

    Tim EA Peto

  • Contact email

    tim.peto@ndm.ox.ac.uk

  • Sponsor organisation

    University of Oxford / Clinical Trials and Research Governance

  • Duration of Study in the UK

    1 years, 6 months, 1 days

  • Research summary

    Coronavirus disease (COVID-19) is a disease caused by the virus SARS-CoV-2. The virus is spread through droplets of saliva or nasal discharge. The disease is easily spread with evidence of viral shedding prior to the onset of symptoms.

    Amongst individuals with COVID-19, a small percentage have the ability to spread the virus relatively easily, and these individuals have been colloquially termed “super-spreaders”. However, there is evidence that many individuals have disease that does not appear to be particularly infectious. The risk of transmitting the virus to household contacts has been reported to be as low as 10% (Luo et al, 2020).

    Currently, the only means to prevent onward transmission of the virus is through physical isolation. The current recommendations are for an enforced isolation period of 14 days for individuals with exposure to the virus. This is in spite of the fact that the given likelihood of these individuals having been infected is extremely low.

    There is a significant negative impact of self-isolation from both a physical and mental health perspective. There is also a large community and economic impact at both a societal and individual level.

    To date, there are no reliable measures of a given individual’s infectivity and there is a limited understanding of why some individuals have high infectivity, "super-spreaders", whereas others have non-transmissible disease. Research in this area could enable a more tailored and pragmatic approach to isolation policies, in addition to preventing onward transmission of the virus. This study will consist of questionnaires and longitudinal sampling of individuals with COVID-19 and their contacts to understand COVID-19 infectivity. Developing a greater grasp of infectivity will likely enable a more personalised approach to COVID-19 management as well as limiting further morbidity and mortality from COVID-19. [Study relying on COPI notice]

  • REC name

    London - West London & GTAC Research Ethics Committee

  • REC reference

    20/HRA/5028

  • Date of REC Opinion

    3 Nov 2020

  • REC opinion

    Further Information Favourable Opinion